Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial. [electronic resource]
Producer: 20190528Description: 845-855 p. digitalISSN:- 2468-1253
- Adult
- Aged
- Antibodies -- blood
- Antineoplastic Agents, Immunological -- adverse effects
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Area Under Curve
- Bevacizumab -- adverse effects
- Biosimilar Pharmaceuticals -- adverse effects
- Camptothecin -- analogs & derivatives
- Colorectal Neoplasms -- drug therapy
- Female
- Fluorouracil -- therapeutic use
- Humans
- Intention to Treat Analysis
- Leucovorin -- therapeutic use
- Male
- Middle Aged
- Neoplasm Metastasis
- Organoplatinum Compounds -- therapeutic use
- Progression-Free Survival
- Therapeutic Equivalency
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.